Get a weekly digest of the latest psychedelic research, new studies, and platform updates delivered to your inbox.
No spam, ever. Unsubscribe anytime.
Low-dose psychedelic sessions in a psychotherapeutic setting -- multiple sessions with gradual dose escalation.
A European therapy model historically developed in Switzerland, the Netherlands, and Germany. Unlike PAP, psycholytic therapy uses low to moderate doses across multiple sessions (typically 6-12 over several months). In Switzerland, this method has been available since 2014 under controlled exemption from the FOPH.
Same receptor pharmacology as PAP but at sub-breakthrough doses, facilitating insight while maintaining ego integrity and verbal communication.